Ozempic vs. Wegovy: Same Drug, Different Use

Ozempic and Wegovy are both semaglutide. Same molecule. Same manufacturer. Same mechanism of action. Yet they carry different brand names, different FDA approvals, different doses, and wildly different insurance coverage. If that sounds confusing, you are not alone -- it is one of the most searched questions in GLP-1 therapeutics right now.

The short answer: Ozempic is approved for type 2 diabetes. Wegovy is approved for weight management and cardiovascular risk reduction. The longer answer involves dosing protocols, regulatory history, off-label prescribing controversies, and a pricing structure that has real consequences for millions of patients.

This guide breaks down every meaningful difference so you can understand what each one does, who it is designed for, and why the distinction matters. For a deeper dive into the pharmacology, see our complete semaglutide guide.

What Is Semaglutide?
Head-to-Head Comparison Table
FDA Approvals: Two Brands, Two Indications
Dosing Differences: Why the Numbers Matter
Weight Loss: What the Clinical Trials Show
Cardiovascular Benefits
The Oral Semaglutide Option
Side Effects: Same Drug, Similar Profile
Cost, Insurance, and the Access Problem
Off-Label Ozempic for Weight Loss
How to Decide Between Ozempic and Wegovy
The Bottom Line
Frequently Asked Questions
References

What Is Semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Novo Nordisk. It mimics the natural GLP-1 hormone your gut releases after eating, which tells the pancreas to produce insulin, slows gastric emptying, and signals the brain that you are full.

The drug exists under three brand names in the United States:

Ozempic -- injectable semaglutide for type 2 diabetes
Wegovy -- injectable and oral semaglutide for chronic weight management
Rybelsus -- oral semaglutide for type 2 diabetes

All three are the same active compound. The differences lie in dose, formulation, and approved indication. For how semaglutide compares to other GLP-1 drugs, see our guides on semaglutide vs. tirzepatide and semaglutide vs. liraglutide.

Head-to-Head Comparison Table

Feature	Ozempic	Wegovy
Active ingredient	Semaglutide	Semaglutide
Manufacturer	Novo Nordisk	Novo Nordisk
FDA-approved for	Type 2 diabetes, CV risk reduction (in T2D), kidney disease progression (in T2D)	Chronic weight management, CV risk reduction (in overweight/obesity with CVD)
Available forms	Weekly injection, daily oral tablet	Weekly injection, daily oral tablet
Max injectable dose	2.0 mg/week	2.4 mg/week
Max oral dose	14 mg/day	25 mg/day
Typical weight loss	8--14% body weight	15--18% body weight
Year FDA-approved	2017 (injection)	2021 (injection), 2025 (oral)
Self-pay cost (2026)	$349/month	$349/month
List price	~$998/month	~$1,350/month
Insurance coverage	Broadly covered for T2D	Often denied for weight loss; better coverage with CVD indication
Pen design	Detachable needles	Built-in needle

FDA Approvals: Two Brands, Two Indications

Ozempic

The FDA approved injectable Ozempic in December 2017 for adults with type 2 diabetes. Its approved indications have since expanded:

Blood glucose control in type 2 diabetes, as an adjunct to diet and exercise
Cardiovascular risk reduction -- lowering the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and established heart disease
Kidney disease progression -- reducing the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease

Weight loss is not on that list. Ozempic has never received FDA approval for weight management. Every Ozempic prescription written solely for weight loss is, by definition, off-label.

Wegovy

Wegovy arrived in June 2021 as the first new FDA-approved weight loss drug since 2014. Its approved indications are:

Chronic weight management in adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia
Cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight -- approved in March 2024 based on the SELECT trial
Pediatric weight management in adolescents aged 12 and older with obesity

In December 2025, the FDA approved the oral Wegovy tablet (semaglutide 25 mg daily), making it the first oral GLP-1 medication approved for weight management. It launched in the U.S. in January 2026.

The regulatory distinction matters -- it determines access, insurance coverage, and what dose a prescriber can legally titrate to under the approved label.

Dosing Differences: Why the Numbers Matter

Both drugs use the same escalation strategy: start low to minimize gastrointestinal side effects, then increase over several weeks to the maintenance dose. But they end at different places.

Ozempic Dose Escalation (Injectable)

Weeks	Dose
Weeks 1--4	0.25 mg/week
Weeks 5--8	0.5 mg/week
Week 9+	1.0 mg/week (standard maintenance)
Optional	2.0 mg/week (if additional glycemic control needed)

Wegovy Dose Escalation (Injectable)

Weeks	Dose
Weeks 1--4	0.25 mg/week
Weeks 5--8	0.5 mg/week
Weeks 9--12	1.0 mg/week
Weeks 13--16	1.7 mg/week
Week 17+	2.4 mg/week (maintenance)

That 0.4 mg gap between Ozempic's maximum (2.0 mg) and Wegovy's maintenance (2.4 mg) is not trivial. It represents a 20% higher dose at the top end, and in the clinical trials, that higher dose translated into meaningfully greater weight loss.

There is also a practical difference with the pens themselves. Ozempic pens require you to attach a disposable needle before each injection. Wegovy pens have a built-in needle -- you click, inject, and discard the entire pen.

Oral Dosing

The oral versions follow similar logic but with different numbers:

Rybelsus (Ozempic's oral counterpart for diabetes): 3 mg, 7 mg, or 14 mg daily
Oral Wegovy (for weight management): escalates from 1.5 mg to 4 mg to 9 mg and finally 25 mg daily

The oral Wegovy tablet at 25 mg delivers weight loss comparable to the 2.4 mg weekly injection, according to the OASIS trial program. For a detailed comparison of oral and injectable semaglutide, see our guide on oral vs. injectable semaglutide.

Weight Loss: What the Clinical Trials Show

Here is where the dosing gap becomes clinically significant.

Ozempic Trials (SUSTAIN Program)

The SUSTAIN trials studied semaglutide at doses of 0.5 mg and 1.0 mg weekly -- the original Ozempic doses -- in people with type 2 diabetes. Weight loss was a secondary endpoint, not the primary goal.

Results at 0.5--1.0 mg:

Average body weight reduction of 4.5--6.5% over 30--56 weeks
Some patients at the 1.0 mg dose achieved up to 6.5% weight loss

At the later-approved 2.0 mg dose (SUSTAIN FORTE):

Average weight loss reached approximately 7--8% over 40 weeks in diabetes patients

These are meaningful for diabetes management, where even 5% weight loss improves insulin sensitivity and cardiometabolic markers. But they are not in the same range as what Wegovy's higher dose achieves.

Wegovy Trials (STEP Program)

The STEP trials -- four large, randomized, placebo-controlled studies -- tested semaglutide 2.4 mg weekly specifically for weight management. Our STEP study breakdown covers each trial in detail. Here are the headline numbers.

STEP 1 (1,961 adults without diabetes, 68 weeks):

Semaglutide group lost 14.9% of body weight vs. 2.4% with placebo
86.4% of participants lost at least 5% of their body weight
69.1% lost at least 10%
50.5% lost at least 15%

STEP 3 (semaglutide + intensive behavioral therapy):

Mean weight loss of 16.0% at 68 weeks

STEP 8 (head-to-head vs. liraglutide 3.0 mg):

Semaglutide produced 15.8% weight loss vs. liraglutide's 6.4%

OASIS 4 (oral Wegovy 25 mg, 307 adults, 64 weeks):

Mean weight loss of 16.6% with full treatment adherence
34.4% of adherent participants lost 20% or more of their body weight

The data is clear: the higher dose used in Wegovy produces roughly double the weight loss seen at Ozempic's standard diabetes doses.

Weight Regain After Stopping

One caveat: the STEP 1 extension study showed participants who stopped semaglutide regained about two-thirds of lost weight within one year. Average weight remained 5.6% below baseline -- some sustained benefit, but a clear signal that semaglutide for weight management is not a short-term intervention.

Cardiovascular Benefits

Both Ozempic and Wegovy now carry cardiovascular indications, but for different patient populations.

Ozempic: CV Benefits in Diabetes

Ozempic's cardiovascular approval is limited to patients with type 2 diabetes and established heart disease. The SUSTAIN 6 trial showed a 26% reduction in the composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke in this population.

Wegovy: The SELECT Trial

The SELECT trial was a game-changer. It enrolled 17,604 adults aged 45 and older who had established cardiovascular disease, a BMI of 27 or higher, and -- here is the key part -- no diabetes.

Results over a median follow-up of approximately 40 months:

20% reduction in major adverse cardiovascular events (MACE) -- the composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke
28% reduction in heart attacks
15% reduction in cardiovascular death
19% reduction in all-cause mortality

These findings led the FDA to expand Wegovy's label in March 2024, making it the first weight loss medication ever approved to reduce cardiovascular risk. The real-world SCORE study of nearly 28,000 patients has since confirmed these benefits outside the trial setting. For patients with heart disease and obesity, Wegovy now has an evidence base that extends into cardiovascular prevention -- a distinction Ozempic does not carry for patients without diabetes.

The Oral Semaglutide Option

The December 2025 approval of oral Wegovy introduced a needle-free path to GLP-1 therapy for weight management. The tablet uses the same SNAC absorption technology found in Rybelsus, protecting the peptide from stomach acid and helping it cross the gastric lining.

The dosing schedule escalates over 12 weeks:

1.5 mg daily for 4 weeks
4 mg daily for 4 weeks
9 mg daily for 4 weeks
25 mg daily (maintenance)

The OASIS 4 trial showed 16.6% mean weight loss at 64 weeks -- essentially matching the injection. The tradeoff: oral semaglutide requires an empty stomach, 4 ounces of plain water, and a 30-minute wait before eating or taking other medications. For a full rundown, see oral semaglutide vs. injectable.

Side Effects: Same Drug, Similar Profile

Because Ozempic and Wegovy contain the same active ingredient, their side effect profiles overlap almost completely. The most common adverse effects are gastrointestinal:

Nausea (reported by 20--44% of participants in clinical trials, dose-dependent)
Diarrhea (roughly 15--30%)
Vomiting (5--25%)
Constipation (10--24%)
Abdominal pain (6--20%)

These side effects are typically worst during dose escalation and tend to subside as the body adjusts. In the STEP 1 trial, only 4.5% of semaglutide participants discontinued due to gastrointestinal issues. Because Wegovy reaches a higher maximum dose (2.4 mg vs. 2.0 mg), GI side effects may be slightly more common at maintenance -- a modest difference, but worth discussing with a prescriber.

Serious Risks

Both carry the same rare but serious warnings:

Thyroid C-cell tumors -- semaglutide carries a boxed warning based on rodent studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Pancreatitis -- cases have been reported; patients should stop the drug if pancreatitis is suspected
Gallbladder disease -- rapid weight loss can increase gallstone risk
Hypoglycemia -- primarily a concern for diabetes patients using semaglutide alongside insulin or sulfonylureas

For practical strategies to reduce discomfort during treatment, see our guide on how to manage GLP-1 side effects.

Cost, Insurance, and the Access Problem

This is where identical molecules diverge into very different patient experiences.

List Prices and Self-Pay Options

As of early 2026, Novo Nordisk has restructured semaglutide pricing following negotiations with the U.S. government:

Price Tier	Ozempic	Wegovy
Monthly list price	~$998	~$1,350
Self-pay (existing patients)	$349/month	$349/month
Introductory self-pay (new patients, through March 2026)	$199/month (0.25 mg and 0.5 mg doses)	$199/month (0.25 mg and 0.5 mg doses)
Oral Wegovy self-pay	N/A	$149--$299/month (dose-dependent)
With commercial insurance	As low as $25/month (savings card)	As low as $0/month (savings card, if covered)

These prices reflect Novo Nordisk's November 2025 price reduction -- down from $499 per month for self-pay patients -- and its introductory $199/month offer for new patients on starting doses.

The Insurance Gap

Here is the problem. Most commercial insurance plans and Medicare Part D cover Ozempic when prescribed for its approved indication: type 2 diabetes. Coverage is relatively straightforward with a diagnosis code for T2D.

Wegovy faces a harder road. Many insurers still classify chronic weight management as elective or cosmetic, and prior authorization requirements can be stringent -- requiring documented BMI thresholds, failed attempts at other weight loss interventions, and specific comorbidities.

That changed somewhat in 2024--2025. Medicare began covering Wegovy for cardiovascular risk reduction in patients with established heart disease and overweight or obesity. Some commercial plans expanded coverage after the SELECT trial. The TrumpRx program negotiated starting doses at $350/month, trending toward $245/month over two years.

Still, many patients whose primary goal is weight loss find Wegovy denied while Ozempic -- the same molecule at a lower dose -- gets approved with a diabetes diagnosis. This asymmetry drives much of the off-label prescribing problem.

Off-Label Ozempic for Weight Loss

Because Ozempic is more accessible through insurance, some patients and prescribers use it as a workaround for weight loss. This is legal -- doctors can prescribe any FDA-approved drug off-label -- but it comes with complications.

The Scale of the Problem

Data from HCCI (Health Care Cost Institute) show the share of Ozempic users without a diabetes diagnosis has risen steadily since the drug's viral moment on social media. CVS Caremark has reported rejecting approximately 84% of Ozempic prior authorizations because the patients did not have a diabetes diagnosis.

Why It Is Not Equivalent to Wegovy

Prescribing Ozempic for weight loss means prescribing it at diabetes doses -- typically 0.5 mg to 1.0 mg weekly, topping out at 2.0 mg. At those doses, patients can expect 5--8% weight loss. That is less than half of what the 2.4 mg Wegovy dose achieves in clinical trials.

Some prescribers titrate Ozempic beyond labeled doses to approximate Wegovy's protocol. This is doubly off-label (off-label indication and off-label dosing) and carries no insurance backstop if problems arise.

The Shortage Fallout

During 2022--2024, surging off-label demand contributed to a national Ozempic shortage that hit type 2 diabetes patients hardest. Some rationed doses, switched to less effective medications, or lost access entirely -- leading to uncontrolled blood sugar and downstream complications.

The FDA shortage officially resolved in February 2025, but the episode exposed the real cost of treating a weight management drug and a diabetes drug as interchangeable based on insurance coverage rather than clinical need.

For patients considering compounded alternatives, our compounded semaglutide vs. brand-name guide covers the safety and regulatory picture.

How to Decide Between Ozempic and Wegovy

The question is not which drug is "better" -- they are the same drug. The question is which indication, dose, and access pathway fits your clinical situation.

Ozempic May Be Right If You:

Have type 2 diabetes and need glycemic control
Are also overweight and would benefit from the secondary weight loss that comes with diabetes-dose semaglutide
Have insurance that covers Ozempic for T2D but denies Wegovy
Need cardiovascular risk reduction and have type 2 diabetes

Wegovy May Be Right If You:

Do not have type 2 diabetes but meet the BMI criteria for chronic weight management (BMI 30+, or 27+ with a weight-related comorbidity)
Want to achieve the maximum weight loss semaglutide can deliver (15--18% body weight)
Have established cardiovascular disease and want the cardiovascular risk reduction supported by SELECT trial data
Prefer the oral tablet option (25 mg daily)
Can access it through insurance or afford the self-pay price

Questions to Ask Your Prescriber

What is my primary treatment goal -- glucose control, weight loss, or cardiovascular risk reduction? The answer points toward the correct brand and dose.
What will my insurance cover? Have your prescriber's office run a benefits investigation before committing.
Am I comfortable with injections, or do I prefer an oral option? The Wegovy pill removes the needle barrier.
What is the plan if I stop treatment? Weight regain after discontinuation is well-documented. Discuss long-term strategy.

For a broader comparison of GLP-1 options, including tirzepatide-based alternatives, see our Ozempic vs. Zepbound comparison.

The Bottom Line

Ozempic and Wegovy are the same molecule prescribed under different rules. The pharmacology is identical. The clinical outcomes differ primarily because the doses differ -- 2.4 mg produces more weight loss and now has dedicated cardiovascular outcome data in people without diabetes, while 1.0--2.0 mg is optimized for glucose control.

The practical reality is messier. Insurance coverage, not pharmacology, often determines which brand a patient ends up on. The result is a system where many people take a lower dose of a drug because their insurer will pay for the diabetes indication but not the weight management one.

If you are considering either medication, the most productive conversation is with a prescriber who understands both the clinical evidence and the insurance realities. The drug is the same. The dose, the approval, and the path to getting it covered are not.

Frequently Asked Questions

Can I switch from Ozempic to Wegovy?

Yes, but it requires a new prescription and typically a new prior authorization. Your prescriber can transition you directly -- for example, if you are on Ozempic 1.0 mg, you might move to Wegovy 1.7 mg and escalate to 2.4 mg. There is no washout period needed since the drug is identical.

Is Wegovy just a higher dose of Ozempic?

Essentially, yes. The maintenance dose of Wegovy (2.4 mg/week) is 20% higher than Ozempic's maximum (2.0 mg/week). But Wegovy also carries different FDA approvals -- weight management and cardiovascular risk reduction without diabetes -- which matters for insurance coverage and appropriate clinical use.

Why does Wegovy cost more if it is the same drug?

The list price difference (~$998/month for Ozempic vs. ~$1,350/month for Wegovy) reflects different market positioning and negotiated payer contracts rather than manufacturing costs. At the self-pay level, Novo Nordisk has equalized them at $349/month as of late 2025.

Will my insurance cover Ozempic for weight loss?

Unlikely. Most insurers only cover Ozempic for its approved indications (type 2 diabetes, cardiovascular and kidney risk in T2D). Off-label prescribing for weight loss is typically denied. Some prescribers work around this with creative coding, but this carries compliance risks.

Does the Wegovy pill work as well as the injection?

The OASIS 4 trial showed the 25 mg oral tablet produced 16.6% weight loss at 64 weeks in adherent patients -- comparable to the 14.9--17.4% range seen in the STEP injection trials. The oral formulation requires strict dosing conditions (empty stomach, plain water, 30-minute fast), which affects real-world adherence.

References

Wilding, J.P.H., et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 2021. DOI: 10.1056/NEJMoa2032183
Lincoff, A.M., et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." New England Journal of Medicine, 2023. DOI: 10.1056/NEJMoa2307563
U.S. Food and Drug Administration. "FDA Approves New Medication for Chronic Weight Management." June 2021.
U.S. Food and Drug Administration. "FDA Approves Wegovy for Cardiovascular Risk Reduction in Adults with Known Heart Disease and Overweight or Obesity." March 2024.
U.S. Food and Drug Administration. "FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss." December 2025.
Novo Nordisk. "Novo Nordisk Launches Introductory Self-Pay Offer for Wegovy and Ozempic for $199 Per Month." November 2025.
Novo Nordisk. "Long-Term Weight Loss Effects of Semaglutide in Obesity Without Diabetes in the SELECT Trial." Nature Medicine, 2024.
Smolderen, K., et al. "Lower Risk of Cardiovascular Events in Patients Initiated on Semaglutide 2.4 mg in the Real-World: Results from the SCORE Study." Diabetes, Obesity and Metabolism, 2025.
Health Care Cost Institute. "The Share of Ozempic Users with Diabetes Has Decreased Over Time, Indicating Increased Off-Label Use." 2024.
Rubino, D., et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs. Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity: The STEP 4 Randomized Clinical Trial." JAMA, 2021.

Table of Contents